BioAge Labs (BIOA) Liabilities and Shareholders Equity (2023 - 2026)

BioAge Labs has disclosed Liabilities and Shareholders Equity across 4 years of filings, most recently posting $397.7 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $397.7 million, up 15.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 26.97% YoY), and the FY2025 annual result was $294.9 million, down 17.68% from the prior year.
• Liabilities and Shareholders Equity came in at $397.7 million for Q1 2026 at BioAge Labs, up from $294.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $397.7 million in Q1 2026 to a low of $25.9 million in Q4 2023.
• The 4-year median for Liabilities and Shareholders Equity is $329.8 million (2024), against an average of $298.1 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 1281.86% in 2024 and retreated 17.68% in 2025, its largest moves.
• BioAge Labs' Liabilities and Shareholders Equity stood at $25.9 million in 2023, then surged by 1281.86% to $358.2 million in 2024, then slipped by 17.68% to $294.9 million in 2025, then soared by 34.85% to $397.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $397.7 million (Q1 2026), $294.9 million (Q4 2025), and $305.1 million (Q3 2025), per Business Quant data.